Biotech Values

[caravon]

IMO,

- ENTA's management has misled its shareholders claiming " a double digit" royalties on V-Pak sale. In reality, ENTA gets 3-5% royalty on V-Pak sale.
- ENTA's management is doing nothing to get a better deal for its shareholders on its future HCV products sale.
- And now, ENTA's management is busy keeping their offices.

PS
A 3-5% royalty range is usually for potential drug candidates licensed before availability of any clinical trials.

If ENTA's management will try to do any "under table" deals, I will be more than glad to participate in legal actions against them.